A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

As the list of health benefits of semaglutide drugs grows, perhaps it is time to think about assessing their impact on people ...

Diabetes and weight loss treatments such as Ozempic and Wegovy, known as GLP-1 agonists, could significantly reduce the risk of developing any type of dementia, according to a meta-analysis of 26 ...

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study, publish… ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, say scientists. While both medications demonstrate neuroprotective ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Of the 26 trials reviewed, 23 reported cases of cognitive impairment or dementia after a six-month follow-up. Participants who took GLP-1 agonists like Ozempic were less likely to show signs of ...

GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...

News Ozempic ingredient linked to reduced dementia risk in diabetes patients, CWRU study shows Published: Jul. 15, 2025, 10:23 a.m.

Business Ozempic linked to lower dementia rate in Oxford study After a year on the drug, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin.

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study ...